Clinical Trial Update: Crossover Post-herpetic Neuralgia (PHN) [Phase 2]

View source ↗

Summary

Phase 2 crossover trial for post-herpetic neuralgia has completed. Sponsor Bristol-Myers Squibb reports the study status as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-herpetic Neuralgia

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Post-Herpetic Neuralgia (PHN) | Phase 2 | Status: COMPLETED